Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

Author(s): Marco Ruella, M.D.^1,2,3; Luca Paruzzo, M.D.^1,2,3; Emeline R. Chong, B.A.¹; Elise A. Chong, M.D.^1,3; Daniel J. Landsburg, M.D.^1,3; Sunita D. Nasta, M.D.^1,3; Pooja Devi, M.D.⁴; Peter Michener, M.S.²; Federico Stella, M.D.²; Alberto Carturan, M.D.^1,2,3; Ellen B. Napier, C.R.N.P.^1,3; Vivianna M. Van Deerlin, M.D., Ph.D.⁴; Patrizia Porazzi, Ph.D.²; Bruce L. Levine, Ph.D.^2,4; Noelle Frey, M.D.³; David L. Porter, M.D.^2,3; Joseph A. Fraietta, Ph.D.^2,4,5; Jakub Svoboda, M.D.^1,3; Carl H. June, M.D.^2,4; Stephen J. Schuster, M.D.^1,2,3;

Source: NEJMoa2518035

Dr. Maen Hussein's Thoughts

After 10 years one third of the heavily pretreated lymphoma patients who had CAR-T therapy stayed disease free.

BACKGROUND

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain.

METHODS

We evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 patients with large B-cell lymphoma and 14 with follicular lymphoma) who had been treated with CTL019 (now called tisagenlecleucel) — autologous T cells expressing CD19-directed, 4-1BB–costimulated chimeric receptors. Lymphoma-free survival was defined as the time from the tisagenlecleucel infusion to relapse or lymphoma-related death. The incidence of non–relapse-related death and second primary cancer was estimated with the Aalen–Johansen method. The data-cutoff date was October 1, 2025.

RESULTS

a median follow-up of 10.1 years (range, 7.9 to 11.5), no relapses had occurred beyond 5.4 years. The 10-year lymphoma-free survival was 32% (95% confidence interval [CI], 14 to 51) among patients with large B-cell lymphoma and 47% (95% CI, 20 to 71) among those with follicular lymphoma. In an analysis that included deaths from any cause, the 10-year progression-free survival was 17% (95% CI, 5 to 34) among patients with large B-cell lymphoma and 29% (95% CI, 9 to 52) among those with follicular lymphoma; the 10-year overall survival was 17% (95% CI, 5 to 34) and 50% (95% CI, 23 to 72), respectively. Persistent grade 2 or 3 neutropenia occurred in 2 patients (5%); no late anemia or thrombocytopenia was observed. A second primary cancer developed in 9 patients (10-year cumulative incidence, 21%). The 10-year non–relapse-related mortality was 18% (14% when deaths related to coronavirus disease 2019 were excluded). Higher CAR-transgene persistence appeared to be associated with long-term response. B-cell aplasia persisted in 44% of patients with a long-term response.

CONCLUSIONS

Among patients with heavily pretreated B-cell non-Hodgkin lymphoma, a single infusion of tisagenlecleucel led to decade-long remissions (lymphoma-free survival) in approximately one third of the patients with large B-cell lymphomas and in nearly one half of those with follicular lymphoma. (Funded by the Richard Berman Family Innovations Center in CLL and Lymphomas and others; ClinicalTrials.gov number, NCT02030834.)

Author Affiliations

¹Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia; ²Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia; ³Department of Medicine, Division of Hematology–Oncology, Hospital of the University of Pennsylvania, Philadelphia; ⁴Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia; ⁵Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial

Progression-free survival was improved in the tafa-len-R-CHOP group vs the R-CHOP with 2-year progression-free survival rates of 71·1vs 62·9% toxicity was higher with tafa-len-R-CHOP with a higher rate of fatal treatment-emergent adverse events, but more overall deaths the RCHOP arm. It is early to add Len taf because of toxicity esp with OS survival and deep response data being immature.

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

Median progression-free survival (PFS) was significantly longer with mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) than with R-GemOx (11.5 months vs 3.8 months). The overall response rate (ORR) was significantly higher with Mosun-Pola compared with R-GemOx (70% vs 40%; P < .0001), with complete response rates of 51% and 24%, respectively. Cytokine release syndrome (CRS) occurred in fewer than 5% of patients.

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Another update demonstrated the superiority of polatuzumab vedotin plus R-CHOP (Pola-R-CHOP) over R-CHOP alone, with improved progression-free survival (PFS) (64% vs 59%). Overall survival (OS) was not statistically significant; however, the hazard ratio was 0.85, with greater benefit observed in high-risk patients.

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma

Minimal residual disease (MRD) testing after two cycles of therapy and at the end of treatment predicted 2-year progression-free survival (PFS) (96% in MRD-negative patients vs 67% in MRD-positive patients). MRD status was more predictive of treatment outcomes than radiographic imaging in this patient population.

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

The ECHELON-3 study showed BV + Len + R is an active and (relatively) tolerable in the rrDLBCL patient group. Interestingly, patients did not have to be CD30+ to see a benefit.